NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · AGRX · USD
Stock price, earnings
Quote as of Aug 22, 2024, 07:58 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Agile Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 42.59% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Agile Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2022 |
|---|
| Mar 22, 2023 |
| -$9.00+14.29% vs estimate |
| $4.00M+29.74% vs estimate |
| Q3 2022 | Nov 7, 2022 | -$11.50-2,513.64% vs estimate | $3.00M+28.65% vs estimate |
|---|
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
€2.94-€0.11 (-3.61%)
Biofrontera AG’s quoted price sits in the lower half of its reported 52-week range, 43.24% below the high.
$0.21-$0.04 (-16.39%)
Simply Better Brands Corp.’s quoted price sits in the lower half of its reported 52-week range, 54.04% below the high.
$0.27+$0.01 (+2.88%)
MGC Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 94.75% below the high.
$0.08$0.00 (0.0%)
RIV Capital Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.66% below the high.
$3.49+$0.05 (+1.45%)
Neoleukin Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.44% below the high.
$3.25+$0.03 (+0.93%)
Guardion Health Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.94% below the high.
